Scott Robinson. "First-in-class TMBIM6 therapeutics: Overcoming limitations in current oncology therapies through ERAD-II induced paraptosis.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e15120